SAXAGLIPTIN LEVELS AND ITS PHARMACOKINETIC APPLICATION IN PRESENCE OF SUCRALOSE IN ANIMALS SERUM BY HPLC METHOD
暂无分享,去创建一个
[1] Miriam F. Ayad,et al. Stability-indicating liquid chromatographic method for determination of saxagliptin and structure elucidation of the major degradation products using LC-MS. , 2015, Journal of chromatographic science.
[2] E. Arora,et al. Combination of PPAR-α Agonist and DPP-4 Inhibitor: A Novel Therapeutic Approach in the Management of Diabetic Nephropathy , 2013 .
[3] S. Schiffman,et al. Sucralose, A Synthetic Organochlorine Sweetener: Overview of Biological Issues , 2013, Journal of toxicology and environmental health. Part B, Critical reviews.
[4] Mei-cun Yao,et al. Development of a rapid UPLC-MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study. , 2012, Biomedical chromatography : BMC.
[5] W. Humphreys,et al. Characterization of the In Vitro and In Vivo Metabolism and Disposition and Cytochrome P450 Inhibition/Induction Profile of Saxagliptin in Human , 2012, Drug Metabolism and Disposition.
[6] M. Fouad,et al. Development and validation of a reversed-phase column liquid chromatographic method for simultaneous determination of two novel gliptins in their binary mixtures with Metformin , 2012 .
[7] W. Humphreys,et al. Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[8] Joshua J. Neumiller,et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[9] Sum Lam,et al. Saxagliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes , 2010, Cardiology in review.
[10] W. Humphreys,et al. Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections , 2009, Drug Metabolism and Disposition.
[11] D. Boulton,et al. P0586 A COMPARISON OF THE SINGLE-DOSE PHARMACOKINETICS AND SAFETY OF SAXAGLIPTIN IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN HEALTHY SUBJECTS , 2009 .
[12] R. McLendon,et al. Splenda Alters Gut Microflora and Increases Intestinal P-Glycoprotein and Cytochrome P-450 in Male Rats , 2008, Journal of toxicology and environmental health. Part A.
[13] M. Shimada,et al. Isolation and Characterization of a New Major Intestinal CYP3A Form, CYP3A62, in the Rat , 2004, Journal of Pharmacology and Experimental Therapeutics.
[14] J. P. Finn,et al. A combined chronic toxicity/carcinogenicity study of sucralose in Sprague-Dawley rats. , 2000, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[15] R. M. Fisher,et al. Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. , 1996, Journal of medicinal chemistry.
[16] T. Masujima,et al. A direct injection method of plasma samples onto a reverse phase column for the determination of drugs. , 1982, Chemical & pharmaceutical bulletin.
[17] M. Evans. Review: Saxagliptin: a review , 2010 .